Use of amantadine in a patient with SARS‐CoV‐2
2020; Wiley; Volume: 93; Issue: 1 Linguagem: Inglês
10.1002/jmv.26179
ISSN1096-9071
AutoresGonzálo Emiliano Aranda-Abreu, José Dolores Aranda‐Martínez, Ramiro Araújo,
Tópico(s)Infectious Encephalopathies and Encephalitis
ResumoJournal of Medical VirologyVolume 93, Issue 1 p. 110-111 LETTER TO THE EDITOR Use of amantadine in a patient with SARS-CoV-2 Gonzalo Emiliano Aranda-Abreu, Corresponding Author Gonzalo Emiliano Aranda-Abreu [email protected] orcid.org/0000-0001-8519-5473 Centro de Investigaciones Cerebrales, Universidad Veracruzana, Xalapa, Veracruz, México Correspondence Gonzalo Emiliano Aranda-Abreu, Centro de Investigaciones Cerebrales/Universidad Veracruzana, Xalapa, Veracruz, México. Email: [email protected]Search for more papers by this authorJosé Dolores Aranda-Martínez, José Dolores Aranda-Martínez Centro Médico Cordobés, Córdoba, Veracruz, MéxicoSearch for more papers by this authorRamiro Araújo, Ramiro Araújo Hospital da Lapa, Porto, PortugalSearch for more papers by this author Gonzalo Emiliano Aranda-Abreu, Corresponding Author Gonzalo Emiliano Aranda-Abreu [email protected] orcid.org/0000-0001-8519-5473 Centro de Investigaciones Cerebrales, Universidad Veracruzana, Xalapa, Veracruz, México Correspondence Gonzalo Emiliano Aranda-Abreu, Centro de Investigaciones Cerebrales/Universidad Veracruzana, Xalapa, Veracruz, México. Email: [email protected]Search for more papers by this authorJosé Dolores Aranda-Martínez, José Dolores Aranda-Martínez Centro Médico Cordobés, Córdoba, Veracruz, MéxicoSearch for more papers by this authorRamiro Araújo, Ramiro Araújo Hospital da Lapa, Porto, PortugalSearch for more papers by this author First published: 15 June 2020 https://doi.org/10.1002/jmv.26179Citations: 23Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Aranda Abreu GE, Hernández Aguilar ME, Herrera Covarrubias D, Rojas Durán F. Amantadine as a drug to mitigate the effects of COVID-19. Med Hypotheses. 2020; 140:109755. 10.1016/j.mehy.2020.109755 PubMedWeb of Science®Google Scholar 2Brenner SR. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects [published online ahead of print May 21, 2020]. J Med Virol. https://doi.org/10.1002/jmv.26030 Google Scholar 3Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020; 3:e208857. 10.1001/jamanetworkopen.2020.8857 PubMedWeb of Science®Google Scholar 4Cortés Borra A. Does amantadine have a protective effect against COVID-19 [published online ahead of print June 04, 2020]. Neurol Neurochir Pol. https://doi.org/10.5603/PJNNS.a2020.0041 Google Scholar Citing Literature Volume93, Issue1Special Issue on New coronavirus (2019‐nCoV or SARS‐CoV‐2) and the outbreak of the respiratory illness (COVID‐19): Part‐VIIIJanuary 2021Pages 110-111 ReferencesRelatedInformation
Referência(s)